Providence Capital Advisors LLC Buys 2,800 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Providence Capital Advisors LLC lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 5.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,600 shares of the medical equipment provider's stock after purchasing an additional 2,800 shares during the quarter. Providence Capital Advisors LLC's holdings in Zimmer Biomet were worth $5,873,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Geode Capital Management LLC raised its position in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock worth $524,942,000 after buying an additional 125,852 shares in the last quarter. Van ECK Associates Corp raised its holdings in Zimmer Biomet by 5.9% during the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after purchasing an additional 218,688 shares in the last quarter. Norges Bank acquired a new stake in Zimmer Biomet in the fourth quarter worth approximately $216,223,000. Hotchkis & Wiley Capital Management LLC boosted its stake in Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider's stock valued at $189,161,000 after purchasing an additional 577,320 shares in the last quarter. Finally, Equity Investment Corp raised its stake in shares of Zimmer Biomet by 57.2% in the 4th quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider's stock worth $107,855,000 after buying an additional 371,653 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Remove Ads

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ZBH. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and increased their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Stifel Nicolaus lifted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a research report on Thursday, January 23rd. JMP Securities reiterated a "market outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Royal Bank of Canada decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $124.15.

Zimmer Biomet Stock Down 0.2 %

Shares of ZBH traded down $0.19 during mid-day trading on Tuesday, hitting $112.99. 305,638 shares of the company's stock were exchanged, compared to its average volume of 1,839,199. The stock has a market cap of $22.49 billion, a price-to-earnings ratio of 25.39, a P/E/G ratio of 1.95 and a beta of 1.04. The firm has a fifty day moving average of $107.26 and a two-hundred day moving average of $107.10. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $130.89.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the business earned $2.20 EPS. On average, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.85%. Zimmer Biomet's payout ratio is currently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.